DGTR Initiates Anti-Dumping Probe on TB Drug
Ethambutol Hydrochloride from China and Thailand Following Complaint by Lupin
Ltd, Supported by Cadila Pharma and Themis Medicare
·
Normal Value Constructed for both China and Thailand
[DGTR Initiation Notification Case No. AD
(OI) – 22/2025 dated 23.09.2025]
·
Product:
Ethambutol Hydrochloride, a bacteriostatic drug used in treating pulmonary
tuberculosis.
·
Countries Involved:
People's Republic of China and the Kingdom of Thailand.
·
Purpose:
To investigate alleged dumping of Ethambutol Hydrochloride into India and its
impact on domestic industry.
·
Ethambutol Hydrochloride is derived from
Ethambutol and used in tablet form due to better stability and solubility.
·
Classified under HS Code 29051490, though
classification is indicative.
·
The imported product is considered
identical to the domestically produced version by Lupin Ltd.
·
Applicant:
Lupin Limited.
·
Other producers: Cadila Pharmaceuticals
(also an importer) and Themis Medicare (ceased production).
·
Lupin is deemed to represent 100% of
eligible domestic production.
·
POI:
April 1, 2024 – March 31, 2025.
·
Injury analysis includes data from
2021–2024.
·
China:
Normal value constructed using Indian cost estimates due to lack of market
economy evidence.
·
Thailand:
Normal value also constructed using Indian cost estimates.
·
Export prices derived from DG Systems
import data.
·
Preliminary findings suggest significant
dumping margins above de minimis levels.
·
Imports are undercutting domestic
prices, suppressing price increases, and causing financial harm to the domestic
industry.
·
Based on prima facie evidence, DGTR
initiates an anti-dumping investigation under Section 9A of the Customs Tariff
Act.
·
Interested parties must submit relevant
information within 30 days.
·
Confidential submissions must be
accompanied by non-confidential versions and justification for confidentiality.
·
Parties failing to cooperate may be
deemed non-cooperative, and findings may be based on available facts.